| Christoforidou A, Pantelidou D, Anastasiadis A, et al.
Hydroxyurea and anagrelide combination therapy in patients with chronic myeloproliferative diseases resistant or intolerant to monotherapy. [Journal Article]
Acta Haematol 2008; 120(4):195-8.
Full Citation | Publisher Full Text | Find Related Articles |
| Emadi A, Spivak JL
Anagrelide: 20 years later. [Journal Article]
Expert Rev Anticancer Ther 2009 Jan; 9(1):37-50.
Abstract | Full Citation | Find Related Articles |
| D'adda M, Micheletti M, Drera M, et al.
The combined use of hydroxyurea and anagrelide allows satisfactory hematologic control in patients with chronic myeloproliferative disorders and thrombocytosis: a report on 13 patients with poor tolerance to hydroxyurea monotherapy. [LETTER]
Leuk Lymphoma 2008 Nov; 49(11):2216-2218.
Full Citation |
| Boban A, Sertić D, Radman I, et al.
[Anagrelide for treatment of patients with essential thrombocythaemia] [English Abstract, Journal Article]
Lijec Vjesn 2008 May-Jun; 130(5-6):141-5.
Abstract | Full Citation | Find Related Articles |
| Penka M, Schwarz J, Pavlík T, et al.
[What is the current treatment of patients with essential thrombocytopenia and other myeloproliferations accompanied with thrombocythemia [corrected] and what can be the predictive sign of the risk of thrombosis in such patients--a report from the registry of patients treated by Thromboreductine] [English Abstract, Journal Article]
Vnitr Lek 2008 Jul-Aug; 54(7-8):775-82.
Abstract | Full Citation | Find Related Articles |
| Hasselbalch HC
Myelofibrosis with myeloid metaplasia: The advanced phase of an untreated disseminated hematological cancer Time to change our therapeutic attitude with early upfront treatment? [JOURNAL ARTICLE]
Leuk Res 2008 Jul 14.
Abstract | Full Citation | Find Related Articles |
| Birgegård G
Long-term management of thrombocytosis in essential thrombocythaemia. [JOURNAL ARTICLE]
Ann Hematol 2008 Jul 16.
Abstract | Full Citation |
| Finazzi G, Barbui T
Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. [JOURNAL ARTICLE]
Leukemia 2008 Jul 3.
Abstract | Full Citation | Find Related Articles |
| Palmblad J, Björkholm M, Kutti J, et al.
TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders. [Journal Article, Research Support, Non-U.S. Gov't]
Int J Med Sci 2008; 5(2):87-91.
Abstract | Full Citation | Find Related Articles |
| Wong RS, Lam LW, Cheng G
Successful rechallenge with anagrelide in a patient with anagrelide-associated cardiomyopathy. [JOURNAL ARTICLE]
Ann Hematol 2008 Feb 26.
Full Citation | Find Related Articles |
   |
